Curative Biotechnology Inc
CUBT evidence brief
What we can confirm
- Market Cap:
- $8.9M
- Next Catalyst:
- Phase2_Start · Dec 31, 2026
What it means
What to watch
Prepared research question
What matters most for CUBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CUBT
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring, in-licensing, and sub-licensing pharmaceutical and medical device products, with an emphasis on FDA-defined orphan diseases.
Key risk: No marketed products
Tracking 6 clinical trials · 5 catalysts for Curative Biotechnology Inc.
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring, in-licensing, and sub-licensing pharmaceutical and medical device products, with an emphasis on FDA-defined orphan diseases.
- Curative Biotechnology Inc is a development-stage biomedical company headquartered in Boca Raton, Florida, formerly known as Connectyx Technologies Holdings Group, Inc., with a name change in November 2020 under new management [sec · filed 2023-01-25].
- The company focuses on products targeted at FDA-defined 'Orphan Diseases' with patient populations under 200,000 in the United States [sec · filed 2023-01-25].
- The company leverages management's experience and business relationships in the Life Science community to acquire therapeutic candidates [sec · filed 2023-01-25].
- Upcoming catalysts include Phase 2 starts for two human umbilical cord mesenchymal stem cell studies (osteonecrosis of femoral head and myelodysplastic syndrome) scheduled for 2026-12-31 [catalyst].
- Patent expiries are anticipated for TEDIZOLID PHOSPHATE (2030-12-31), FIDAXOMICIN (2034-05-28), and CEFTOLOZANE SULFATE/TAZOBACTAM SODIUM (2035-08-14) [catalyst].
What works
- The company targets FDA-defined orphan diseases, which may offer regulatory incentives and reduced competition [sec · filed 2023-01-25].
- Management has experience and business relationships in the Life Science community to acquire therapeutic candidates [sec · filed 2023-01-25].
- The company has a pipeline of stem cell therapies entering Phase 2 trials, indicating progression in clinical development [catalyst].
What to weigh
- The company is a development-stage entity with no marketed products or revenue streams described in the provided filings [sec · filed 2023-01-25].
- Financial details such as cash position, net loss, or accumulated deficit are not provided in the available chunks, indicating potential lack of recent financial transparency [sec].
- The company's business model relies on in-licensing and sub-licensing, which may involve dependency on third-party intellectual property and partnerships [sec · filed 2023-01-25].
- Clinical programs are still in early phases (Phase 1/2), with no data on efficacy or safety outcomes provided in the chunks [catalyst].
From the filings
Quoted directly from source documents.
The company leverages management's experience and relationships to acquire therapeutic candidates.
“The Company leverages management's experience and business relationships in the Life Science community to acquire therapeutic candidates that fit within the company's business model; finding programs that can be acquired”
SEC filings · January 25, 2023
Phase 2 start for osteonecrosis of femoral head study with hUC-MSC is scheduled for 2026-12-31.
“2026-12-31] Phase2_Start: Phase2_Start: The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)”
Catalysts
Phase 2 start for myelodysplastic syndrome study with hUC-MSC is scheduled for 2026-12-31.
“2026-12-31] Phase2_Start: Phase2_Start: Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)”
Catalysts
Catalyst timeline
- 2026-12-31 · Phase2_Start: The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) — Initiation of Phase 2 trial for stem cell therapy in bone necrosis; watch for enrollment and interim data.
- 2026-12-31 · Phase2_Start: Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS) — Initiation of Phase 2 trial for stem cell therapy in MDS; watch for safety and efficacy signals.
- 2030-12-31 · Patent_Expiry · TEDIZOLID PHOSPHATE — Patent expiry for NDA205436; may open market to generic competition.
- 2034-05-28 · Patent_Expiry · FIDAXOMICIN — Patent expiry for NDA213138; may affect revenue from this antibiotic.
- 2035-08-14 · Patent_Expiry · CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM — Patent expiry for NDA206829; potential generic entry for this combination antibiotic.
Risks & what to watch (4)›
Key risks
- No marketed products — The company is development-stage with no revenue-generating products described in filings [sec · filed 2023-01-25].
- Lack of recent financial data — No cash position, net loss, or accumulated deficit figures are provided in the available chunks [sec].
- Early-stage clinical pipeline — Clinical programs are in Phase 1/2 with no efficacy or safety data disclosed [catalyst].
- Dependence on licensing — Business model relies on in-licensing/sub-licensing, creating dependency on third-party IP [sec · filed 2023-01-25].
What to watch
- Initiation of Phase 2 trials for hUC-MSC in osteonecrosis of femoral head and myelodysplastic syndrome, both scheduled for 2026-12-31 [catalyst].
- Patent expiries for TEDIZOLID PHOSPHATE (2030-12-31), FIDAXOMICIN (2034-05-28), and CEFTOLOZANE SULFATE/TAZOBACTAM SODIUM (2035-08-14) which may affect market exclusivity [catalyst].
- Any future financial disclosures or updates on cash position and accumulated deficit, as current filings lack recent figures [sec].
Sources: Catalysts · SEC filings · Generated September 29, 2026 · How we verify sources →
Run Curative Biotechnology Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Curative Biotechnology Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Curative Biotechnology Inc?
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring, in-licensing, and sub-licensing pharmaceutical and medical device products, with an emphasis on FDA-defined orphan diseases.
What is Curative Biotechnology Inc's next catalyst?
Curative Biotechnology Inc's next tracked catalyst is a Phase2_Start event — "Phase2_Start: The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)" — expected December 31, 2026.
Who is the CEO of Curative Biotechnology Inc?
Mr. I. Richard Garr Esq., J.D. is the chief executive officer of Curative Biotechnology Inc (CUBT).
Where is Curative Biotechnology Inc headquartered?
Curative Biotechnology Inc (CUBT) is headquartered in Palm Beach Gardens, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.